Investorideas.com

Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


investorideas.com - A Leading Global Investor Website for Biotech Industry Stocks

Investing in biotechnology stocks, pharma, medical technology and telemedicine has never been more exciting for investors with all of the new breakthroughs in technology and health. Let Investor Ideas help you find your next big idea in the sector with our free stock directories and news alerts. Don't miss out on the chance to invest in the future of healthcare and technology!

Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech Stocks

Investorideas Featured Company: Aethlon Medical, Inc. (NASDAQ: AEMD)

Aethlon Medical, Inc. (NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Get news alerts on this company!

Biotech News

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Announces Pricing of $4.7 Million Public Offering
SAN DIEGO - May 15, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles From Cancer Patient Plasma
SAN DIEGO - May 10, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles (EVs) from plasma.

Healthcare Stocks in Play - INVO Bioscience (Nasdaq: INVO) Soars on Fourth Quarter and Full Year 2023 Financial Results
April 17, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas, including biotech and pharma stocks reports on breaking news on INVO Bioscience, Inc. (Nasdaq: INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics

Pharma Stocks in Play - Jaguar Health, Inc. (NASDAQ: JAGX) Spikes on Volume of over 500 Million on News of Licensing FDA-Approved Oral Mucositis Product
April 16, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas, including biotech and pharma stocks reports on breaking news on Jaguar Health, Inc. (NASDAQ:JAGX), a commercial stage pharmaceuticals company

Biopharma Stocks in Play - Palisade Bio, Inc. (Nasdaq: PALI) Soars on News it Demonstrated Bioactivation of PALI-2108 In Ex-Vivo Study
April 16, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas, including biotech and pharma stocks reports on breaking news on biopharma stock Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.

Biopharma Stocks in Play - PaxMedica, Inc. (NASDAQ: PXMD) Soars on milestone enabling New Drug Application (NDA) to FDA
April 12, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas, including biotech and pharma stocks reports on breaking news on biopharma stock PaxMedica, Inc. (NASDAQ:PXMD), focused on advancing treatments for neurological disorders.

Biotech Stocks in Play - Rallybio Corporation (Nasdaq: RLYB) Soars on Collaboration News and Equity Investment of $6.6 million from Johnson and Johnson Innovation
April 11, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases

Biopharma Stock News Bite - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Spikes on News Potential Treatment for Alcohol Use Disorder
April 10, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news.

Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals
April 8, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance

Are Biotech Stocks the Cure for Today's Investors? (TSX: AIDX) (Nasdaq: XFOR) (Nasdaq: RCKT) (NYSE: AUNA)
April 8, 2024 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sectors.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

PurMinds NeuroPharma Appoints Vanessa Williamson as Chief Business Officer
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - May 23, 2024) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders, today announced that Vanessa Williamson has joined the company as Chief Business Officer effective May 20, 2024."We are thrilled to welcome Vanessa to the...

Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine
Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the Company's wholly-owned subsidiary, Securedose Synthetics Inc. ("SecureDose") has signed an Letter of Intent ("LOI") on the 16th of May, 2024 with a Canadian controlled...

Therma Bright Announces up to $1,000,000 Unit Offering
Toronto, Ontario--(Newsfile Corp. - May 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 100,000,000 units priced at $0.01 per unit for total proceeds of $1,000,000 (the "Offering"). Each unit will be comprised of one common share in the capital of the Company and...

Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent
Halifax, Nova Scotia--(Newsfile Corp. - May 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company's Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University. Dr. Giacomantonio leads a productive translational research group at Dalhousie University and...

PurMinds Chief Scientific Officer to Speak at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - May 21, 2024) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders, today announced that Professor Alan P. Kozikowski, Ph.D., Chief Scientific Officer, will be presenting at the 4th Annual Psychedelic Therapeutics and Drug...

Subscribe to Biotech News